<DOC>
	<DOCNO>NCT02358863</DOCNO>
	<brief_summary>The purpose study determine whether molecular profile-directed therapy ( otherwise know personalized treatment ) improve effectiveness standard chemotherapy combination patient esophagogastric adenocarcinoma . A series test perform sample tumor ; base result test , patient assign chemotherapy treatment .</brief_summary>
	<brief_title>Molecularly Tailored Therapy Patients With Metastatic Cancer Esophagus Stomach</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Advanced , measurable metastatic esophagogastric adenocarcinoma RECIST criterion Patients surgery radiotherapy without neoadjuvant adjuvant chemotherapy ( washout period least 1 month ) Patients eligible resection chemotherapy na√Øve Patients HER2 ( ) status Patients tumor deposit ( ) easily accessible ultrasound CT guidance Patients must adequate organ function Patients must provide write informed consent Active concurrent malignancy , superficial , nonsquamous cell carcinoma skin uterine cervix , within past three year ECOG performance status bad 2 Prior oral intravenous chemotherapy metastatic disease Patients comorbidities prevent able receive chemotherapy regimen cardiac ejection fraction 45 % great</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>